ARTICLE | Clinical News
VPI-013: Phase II started
July 5, 2004 7:00 AM UTC
Vela started a double-blind, placebo-controlled U.S. Phase II trial in 250 patiens. The company in-licensed the compound from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan). ...